- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04007874
Oral Contraceptive Pill Compared With Vitamin E in Women With Migraine (WHATT)
Open-label Randomized Controlled Trial for the Effects of Continuous Ethinylestradiol/Levonorgestrel (30/150 μg/Day) Compared With Vitamin E (400 IU/Day) in the Treatment of Menstrually-related Migraine and Migraine During Perimenopause
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: The prevalence of migraine is three times higher in women than in men. Clinical and epidemiological studies suggest a prominent role for sex hormones in female migraine patients. Menstruation is an important factor increasing the susceptibility for an upcoming attack. Perimenstrual migraine attacks are also more disabling, longer lasting, and more difficult to treat than other attacks. Hormonal fluctuations during menopausal transition are associated with increased susceptibility for migraine as well, whereas hormonal changes in migraine during pregnancy seem to be associated with decreased attack frequency. Thus, sex hormonal conditions seem to affect the susceptibility for migraine attacks in women, but there is a lack of understanding the underlying pathophysiological mechanism. Currently, there is no clear evidence-based hormonal intervention for the treatment of migraine in women. The investigators hypothesize that continuous daily use of an oral contraceptive pill will be an effective, well-tolerated preventive treatment for 1) menstrually-related migraine and 2) perimenopausal migraine.
Objective: To study the efficacy of continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related and perimenopausal migraine.
Study design: Open-label randomized controlled trial. Study population: Women with menstrually-related or pure menstrual migraine and women with perimenopausal migraine.
Intervention: Continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day).
Primary endpoint: Change in monthly migraine days from baseline to the last 4 weeks of treatment (weeks 9-12).
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The study will encompass a period of 4 months (1 baseline month and 3 treatment months). Patients have to fill out daily headache diaries throughout the study using a web-based app (≈ 5 min). Patients visit the headache clinic thrice, once for inclusion, once during the baseline period and once after 3 months of therapy (duration ≈ 1 hour). During the first and last visit blood samples will be taken. Patients will be contacted twice during follow-up to evaluate (S)AE's. Treatment with the oral contraceptive pill is accompanied by a very low risk of developing thromboembolisms. Participation might benefit participants by reducing their migraine attack frequency or intensity.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Britt WH van der Arend, MSc
- Phone Number: +31715266065
- Email: B.W.H.van_der_Arend@lumc.nl
Study Locations
-
-
Zuid Holland
-
Leiden, Zuid Holland, Netherlands, 2333 ZA
- Recruiting
- Leiden University Medical Center
-
Contact:
- Britt WH van der Arend, MD
- Phone Number: +31715266065
- Email: B.W.H.van_der_Arend@lumc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female
- Premenopausal with menstrual migraine OR migraine during the early menopausal transition phase (a difference of 7 days or more in length of consecutive cycles, which should occur at least twice in a period of 12 menstrual cycles)
- Demonstrated at least 80% compliance with eDiary during baseline period
- No or stable for at least two months on prophylactic medication
Exclusion Criteria:
- Smoking
- Migraine with aura
- Chronic migraine with 15 or more headache days per month/with 8 or more migraine days per month
- Medication-overuse headache (ICHD-3 criteria)
- Women who are breastfeeding, pregnant, or planning to become pregnant
- Oral contraceptive use and not willing to undergo washout period (stop for two consecutive months)
- Vitamin E use at start of the study
- Use of other sex hormone containing treatments
- Increased risk of VTE: history of VTE or thrombophlebitis, hereditary predisposition for VTE (APC resistance, protein C or S deficiency, antithrombin deficiency), VTE in first-degree family member at young age, long term immobilisation
- Increased risk of ATE: history of ATE, hereditary predisposition for ATE (hyperhomocysteinemia, antiphospholipid antibodies), ATE in first-degree family member at young age, diabetes mellitus, total cholesterol ≥ 6.5
- Other contraindication for oral contraceptives: liver malignancy, schistosomiasis, HIV/aids, use of immunosuppressives, tuberculosis, sex-hormone-dependent malignancies (breast, endometrial or ovary carcinomas), pancreatitis, vaginal bleeding with unknown cause, other diseases that can influence vessels (malignancies, heart valve disorders, atrial fibrillation, SLE, haemolytic uremic syndrome, chronic inflammatory bowel disease, sickle cell disease)
- Contraindication for vitamin E: vitamin K deficiency
- Hypersensitivity for any of the compounds in oral contraceptive or vitamin E
- Spontaneous postmenopausal status (menstrual bleedings have ceased for 12 consecutive months)
- Iatrogenic postmenopausal status
- Inability to complete the electronic diary in an accurate manner
- Any serious illness that can compromise study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ethinylestradiol/levonorgestrel
Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
|
Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
Other Names:
|
Active Comparator: Vitamin E
Vitamin E 400 IU oral capsules once daily for 3 months
|
Vitamin E 400 IU oral capsules once daily for 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of migraine days
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in monthly migraine days
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of headache days
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in monthly headache days
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Number of migraine attacks
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in monthly migraine attacks
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Number of probable migraine attacks
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in monthly probable migraine attacks
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Number of 50% responders
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Patients who had ≥50% reduction in the number of migraine days
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
(Serious) adverse events
Time Frame: Up to 3 months
|
Occurrence of adverse events and serious adverse events
|
Up to 3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of 75% responders
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Patients who had ≥75% reduction in the number of migraine days
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Number of complete responders
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Patients who had 100% reduction in the number of migraine days
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Number of acute treatment days
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in monthly acute treatment days
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Mean migraine severity score/day
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in migraine severity (four-point anchored scales (0=none, 1=mild, 2=moderate, and 3=severe))
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Mean migraine-related symptom severity score/day
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in migraine-related symptom severity (four-point anchored scales (0=none, 1=mild, 2=moderate, and 3=severe))
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Migraine-Specific Quality of life questionnaire (MSQ)
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in Migraine-Specific Quality of life questionnaire (MSQ) total score (range from 14 (mild impact) to 84 (severe impact))
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Headache Impact Test (HIT-6)
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in Headache Impact Test (HIT-6) total score (range between 36 (mild impact) - 78 (severe impact))
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Perceived Stress Scale (PSS)
Time Frame: From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Change in Perceived Stress Scale (PSS) total score (range between 0 (mildly stressed) - 40 (severely stressed))
|
From baseline to the last 4 weeks of treatment (weeks 9-12)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gisela M Terwindt, MD,PhD, LUMC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Estrogens
- Micronutrients
- Vitamins
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Antioxidants
- Contraceptives, Oral, Hormonal
- Levonorgestrel
- Ethinyl Estradiol
- Vitamin E
- Ethinyl estradiol, levonorgestrel drug combination
Other Study ID Numbers
- WHATT
- 2018-004096-12 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Ethinylestradiol/levonorgestrel
-
HRA PharmaCompletedEmergency ContraceptionSweden, Netherlands, United Kingdom
-
University of CagliariUnknown
-
Boehringer IngelheimCompleted
-
Novo Nordisk A/SRecruitingHealthy Volunteers (Non-alcoholic Steatohepatitis)Austria
-
Karolinska University HospitalKarolinska InstitutetUnknown
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesSweden
-
IVI MadridCompleted
-
EstetraCompletedContraception | Liver Metabolism | Hemostasis ParameterNetherlands
-
NobelpharmaCompleted